Hepatitis C: the path towards effective universal therapy.

Abstract : The worldwide burden of hepatitis C virus (HCV) infection is a major public health concern. New direct antiviral agents (DAAs) have revolutionised the management of HCV infection, with eradication rates higher than 90%. However, their high cost has precluded their widespread use, leading to restrictive conditions of prescription in many countries. DAAs have been available to all people living in France who are infected with HIV for 2 years (fi rst via temporary authorisation and then via marketing authorisations) regardless of their liver fi brosis stage.
Type de document :
Article dans une revue
Lancet, Elsevier, 2016, 388 (10049), pp.1051-1052
Liste complète des métadonnées

https://hal.archives-ouvertes.fr/hal-01509587
Contributeur : Pascal Cholley <>
Soumis le : mardi 18 avril 2017 - 11:16:18
Dernière modification le : mardi 10 octobre 2017 - 13:48:57

Identifiants

  • HAL Id : hal-01509587, version 1
  • PUBMED : 27628513

Citation

Lionel Piroth, Christian Rabaud, Rey Dang, Jean-Luc Schmit, Catherine Chirouze, et al.. Hepatitis C: the path towards effective universal therapy.. Lancet, Elsevier, 2016, 388 (10049), pp.1051-1052. 〈hal-01509587〉

Partager

Métriques

Consultations de la notice

29